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Aims Remote ischaemic preconditioning (RIPC) by inducing brief ischaemia in distant tissues protects the heart against
myocardial ischaemia-reperfusion injury (IRI) in children undergoing open-heart surgery, although its effectiveness
in adults with comorbidities is controversial. The effectiveness and mechanism of RIPC with respect to myocardial
IRI in children with tetralogy of Fallot (ToF), a severe cyanotic congenital cardiac disease, undergoing open heart
surgery are unclear. We hypothesized that RIPC can confer cardioprotection in children undergoing ToF repair
surgery.
...................................................................................................................................................................................................
Methods
and results
Overall, 112 ToF children undergoing radical open cardiac surgery using cardiopulmonary bypass (CPB) were
randomized to either a RIPC group (n= 55) or a control group (n= 57). The RIPC protocol consisted of three
cycles of 5-min lower limb occlusion and 5-min reperfusion using a cuff-inflator. Serum inflammatory cytokines and
cardiac injury markers were measured before surgery and after CPB. Right ventricle outflow tract (RVOT) tissues
were collected during the surgery to assess hypoxia-inducible factor (Hif)-1a and other signalling proteins. Cardiac
mitochondrial injury was assessed by electron microscopy. The primary results showed that the length of stay in
the intensive care unit (ICU) was longer in the control group than in the RIPC group (52.30 ± 13.43 h vs.
47.55 ± 10.34 h, respectively, P= 0.039). Patients in the control group needed longer post-operative ventilation time
compared to the RIPC group (35.02 ± 6.56 h vs. 31.96 ± 6.60 h, respectively, P= 0.016). The levels of post-operative
serum troponin-T at 12 and 18 h, CK-MB at 24 h, as well as the serum h-FABP levels at 6 h, after CPB were signifi-
cantly lower, which was coincident with significantly higher protein expression of cardiac Hif-1a, p-Akt, p-STAT3,
p-STAT5, and p-eNOS and less vacuolization of mitochondria in the RIPC group compared to the control group.
...................................................................................................................................................................................................
Conclusion In ToF children undergoing open heart surgery, RIPC attenuates myocardial IRI and improves the short-term
prognosis.
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Introduction
Tetralogy of Fallot (ToF) is a severe congenital cyanotic cardiac dis-
ease for which the outcomes are more unfavourable than other types
of simple congenital heart diseases, even following surgical repair.
Protection of the organs, especially the heart, of children with ToF
against ischaemia-reperfusion injury (IRI) during the surgery is neces-
sary to improve their prognosis.
The common goal of cardioprotective techniques is to initiate en-
dogenous mechanisms that can reduce the effects of IRI.1 Remote is-
chaemic preconditioning (RIPC) is a noninvasive and clinically
relevant strategy of protection whereby acute intermittent ischaemia
is induced at a distant site to protect against IRI in remote organs,
including the heart.2
The mechanistic pathway linking the remote organ or tissue to the
heart is currently unclear, although several mechanisms have been
proposed, including neural pathways, humoral pathways, and sys-
temic responses. RIPC involves the regulatory phosphorylation of a
number of key intracellular proteins that propagate the signalling for
prosurvival metabolic control in the heart. In particular, the inhibition
of the opening of mitochondrial permeability transition pore (mPTP)
in the heart has been proposed as a major cardioprotective mechan-
ism in the setting of RIPC.3
Protection against IRI is of the utmost importance in children
undergoing heart surgery, as prolonged periods of cardioplegic arrest
and cardiopulmonary bypass (CPB) are often required. RIPC pro-
vides clinically significant protection in children undergoing open
heart surgery with CPB for congenital heart defects,4 although the ef-
fectiveness of RIPC cardioprotection in adult patients undergoing
cardiac surgery remains controversial,5–8 which may be largely attrib-
utable to confounding variables9 and/or the choice of anaesthetics,7,8
which interfere with the cardioprotection by RIPC.10 However, ToF
is a severe cyanotic congenital heart condition, and an oxygen deficit
could remain as a consequence of right ventricle outlet tract stenosis;
the impact of RIPC on myocardial protection in the setting of chronic
hypoxia in children is largely unknown. Therefore, we aimed to ex-
plore the cardioprotective effect of RIPC in children undergoing re-
pair for ToF and to determine the impact of RIPC on the
phosphorylation/activation status of the key molecules involved in
preconditioning cardioprotection and on the post-operative
prognosis.
Methods
Patient recruitment and allocation
This study was approved by the Wuhan Union Hospital Human Ethics
Committee and registered in the Chinese Clinical Trial Registry (NO.
Chi-CTR-TRC-09000457). Written informed consent was obtained
from the patient’s guardian before enrolment in the study.
The sample size was determined based on our preliminary study of
RIPC in children, which aimed to detect differences in clinical outcomes.11
A prolonged intensive care unit (ICU) stay after open heart surgery has a
strong association with poor perioperative cardiac function,12 and peri-
operative complications are the strongest predictors of post-operative
length of stay (LOS) in the ICU.13 Additionally, a prolonged ICU stay is a
powerful predictor of adverse outcomes after cardiac operations both
immediately and in the long-term.14 Therefore, the sample size was
determined to be adequate based on the following conditions: RIPC to
reduce the ICU stay time by 3 h with a power of 0.85, a two-sided signifi-
cance level a of 0.05, and a common variance (Sc2) of 16. Based on the
formula for calculating the sample size,15 the sample size required per
group was 32. Thus, we aimed for a sample size of n= 60 per group,
which would yield ample statistical power.
Patients diagnosed with ToF (n= 154), aged between 3 months to
3 years old, undergoing elective radical surgical repair of ToF with stand-
ard blood cardioplegia and CPB were recruited, and 120 patients were
randomized to the RIPC or control group. Among these 120 patients, the
guardians of 39 patients also gave consent to allow the use of right ven-
tricle outflow tract (RVOT) tissue and blood samples for research pur-
poses (20 patients in the control group, 19 patients in the RIPC group).
Children with chromosomal defects, airway and parenchymal lung dis-
ease, immunodeficiency, severe malnutrition, or blood disorders were
excluded. However, 8 patients did not receive allocated treatment
because of operation cancellation or a change in the surgical approach
(3 cases in the control group and 5 cases in the RIPC group), as shown in
Figure 1.
Randomization and blinding
After the sample size was determined, 120 patients were allocated into
the control group or the RIPC group by block randomization. For this, 10
patients in each block (12 blocks in total) were randomized on a 1:1 basis
into the two groups. Codes were computer-generated and kept in sealed
envelopes at a central location. For each patient randomized, the next
available code was used. On the day of surgery, patients were assigned to
undergo either remote ischaemic preconditioning or no ischaemic pre-
conditioning (control group).
The randomized patients were anaesthetized by an anaesthesiologist
who was not involved as an investigator in the study. Envelopes were
opened after the general anaesthesia induction by another anaesthesiolo-
gist who would perform remote ischaemic preconditioning or not ac-
cording to the grouping. The sample collection, clinical follow-ups and
laboratory research were carried out by different researchers who were
unaware of the grouping. When the research was completed, all the data
were sent to a statistician who was aware of the grouping. The patients,
cardiac surgeons, and intensive-care physicians were unaware of the
treatment assignments.
RIPC and surgical procedures
All preoperative medications were omitted on the day of surgery, and no
premedication was given before surgery. The volatile anaesthetic sevo-
flurane (8% by volume) was given by mask with pure oxygen immediately
after the patient entered the operation room. One minimum alveolar
concentration (MAC) of sevoflurane was inhaled after the patient lost
consciousness. During anaesthesia induction, patients received i.v. mida-
zolam (0.15–0.25 mg/kg), fentanyl (5–10 mg/kg), and the neuromuscular
blocking agent rocuronium (0.6–1.2 mg/kg). Anaesthesia was maintained
with midazolam, sufentanil, and the neuromuscular blocking agent by con-
tinuous infusion, and sevoflurane was inhaled when needed.
Following the insertion of radial arterial catheters, RIPC was induced
by three cycles of 5 min of lower limb ischaemia and 5 min of reperfusion
using a blood-pressure cuff inflated to a pressure 30 mm Hg greater than
the systolic arterial pressure measured via the radial arterial line. The pa-
tients in the control group underwent sham placement of the blood pres-
sure cuff around the leg without inflation. Blood flow interruption and
restoration were monitored by pulse-oximetry. Thereafter, a jugular vein
central venous catheter was inserted. There were 55 to 65 min intervals
(no significant difference between groups) between the completion of
the RIPC protocols and the initiation of CPB in both groups.
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.All children underwent radical surgical repair of ToF using standard
CPB techniques with blood cardioplegia. Modified ultrafiltration was car-
ried out in all children. Inotropic therapy was standardized to a treatment
algorithm instituted to treat a mean radial arterial blood pressure of
60 mm Hg, despite optimization of the preload, afterload, and heart
rate.16
Blood analysis
The patients who gave consent for heart tissue and blood collection
were randomly assigned to control (n= 20) or RIPC (n= 19) groups.
Arterial blood was sampled from the arterial catheter for the measure-
ment of the cytokines interleukin (IL)-8 and IL-10, tumour necrosis factor
(TNF)-a, and the levels of serum creatinine, troponin T (TnT), creatine
kinase-MB (CK-MB), and human fatty acid-binding protein (hFABP)
(Supplementary material online, Method).
Tissue protein extraction and determination
by western blot analysis
After CPB was established, right ventricle outflow tract (RVOT) tissues
were cut by the surgeon to broaden the right ventricle outflow tract sten-
osis. The tissue protein was extracted and processed for Western blot
analysis of phosphorylated Akt (pAkt) (Ser473), Akt (), p-STAT3
(Tyr705), STAT3, p-STAT5 (Tyr694), STAT5, p-PTEN, PTEN, p-eNOS
(Ser1177), eNOS, and Hif-1a (Supplementary material online, Method).
Electron microscopy
Each RVOT heart tissue sample was cut into two 1 mm,3 and was pro-
cessed for mitochondrial morphological analysis (Supplementary material
online, Method). The mitochondrial surface-to-volume ratio (Sv-
ratioMi)
17 and morphometric cellular oedema index (CEI)18,19 were
determined to evaluate the ischaemia-induced swelling of cardiomyo-
cytes. A 48-point grid with angles was projected onto each test field to
determine the Sv-ratioMi by the point and intersection counting method
as described.20 The CEI was calculated from the volume densities of the
mitochondria, sarcoplasm and myofibrils as described.18
Statistical analysis
The data are presented as the means ± SD. The comparison of enumer-
ated data between the treatment groups was conducted using the chi-
square test, while an unpaired t-test was applied to compare measure-
ment data where appropriate. Measurements taken across the time
course were assessed using repeated measures ANOVA with post hoc
comparisons to evaluate any significant effect of group (control vs. RIPC)
or time and/or any significant interaction between group and time. The
GraphPad version 5.0 statistical program (GraphPad Software Inc., San
Diego, CA, USA) and SPSS version 19.0 for Windows (IBM Corporation,
Armonk, NY, USA) were used for the statistical analyses. A value of
P< 0.05 was considered as statistically significantly different.
Results
Patient anthropometric data and
perioperative conditions
As shown in Table 1, the data of intra-operative parameters and post-
operative parameters, including ventilation time, duration of ICU
Figure 1 Trial flow diagram.
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Table 1 Patients’ perioperative, introperative, and postoperative characteristics
Control (n557) RIPC(n555) P-value
Preoperative parameters
Male/female (n, n) 32/25 30/25 0.87
Age, month 11.19±6.22 10.51±6.66 0.58
Weight, kg 9.14±2.81 8.86±2.85 0.59
SpO2, % 96.84±4.26 98.00±3.17 0.11
RVOT, cm 1.07±0.23 1.12±0.26 0.25
Aorta overriding ratio, % 35.09±9.84 32.36±9.81 0.15
Ejection fraction, % 63.86±5.67 64.82 ±4.61 0.33
MAP, mm Hg 56.12±3.50 55.60±3.29 0.42
CVP, cmH2O 12.42±3.64 12.20±2.85 0.72
Intraoperative parameters
Temperaturea, C 30.85±0.86 30.76±0.92 0.60
CPB time, min 109.4±20.2 108.3±20.7 0.79
TACC time, min 46.37±9.42 47.73±9.07 0.44
RVOT sample collect, min 13.05±2.26 12.45±1.76 0.35
MAP during CPB, mm Hg 43.40±3.78 44.15±4.41 0.34
CVP 9.58±1.05 9.26±1.04 0.10
Postoperative parameters
CVP 0h 12.67±1.52 12.53±1.83 0.66
Ventilation time, h 35.02±6.56 31.96±6.60 0.016*
Oxygenation index 0h 138.2±22.5 139.1±23.9 0.84
Oxygenation index 12h 182.5±21.4 187.9±17.3 0.14
Oxygenation index 24h 224.6±32.1 235.6±30.5 0.10
ICU stay, h 52.30±13.43 47.55±10.34 0.038*
Hospital stay, d 15.56±2.77 15.13±2.18 0.37
RPP 0h 11887±1087 11690±1230 0.37
RPP 6h 11951±1798 12043±1162 0.75
RPP 12h 10282±907 9769±1682 0.046*
RPP 24h 9781±881 9598±999 0.31
0h MAP, mm Hg 55.35±3.73 55.64±3.96 0.70
6h MAP, mm Hg 54.37±5.20 54.11±5.50 0.80
12 MAP, mm Hgh 53.81±4.27 54.62±4.54 0.33
24h MAP, mm Hg 55.96±4.69 56.42±3.84 0.58
48h MAP, mm Hg 56.05±4.40 57.22±4.28 0.16
0h IScore, mcg/kg/min 14.17±1.36 13.53±1.44 0.018*
3h IScore, mcg/kg/min 12.25±1.27 11.74±1.50 0.056
6h IScore, mcg/kg/min 11.03±1.37 10.51±1.24 0.035*
12h IScore, mcg/kg/min 10.09 ±1.51 9.63±1.39 0.097
24h IScore, mcg/kg/min 8.84±1.72 8.60±1.45 0.41
24h (ALT), U/L 36.70±8.80 35.58±8.42 0.49
24h Creatinine, umol/L 37.04±15.69 40.87±18.72 0.24
Postoperative complications
ARF I, n(%) 34(59.65%) 24(43.64%) 0.09
ARF II, n(%) 13(22.81%) 9(16.36%) 0.39
Dialysis therapy, n(%) 6(10.53%) 4(7.27%) 0.74
LCOS, n(%) 12(21.05%) 8(14.55%) 0.46
Reintubation, n(%) 7(12.28%) 5(9.09%) 0.76
Pneumonia, n(%) 18(31.58%) 14(25.45%) 0.53
Hospital death, n(%) 2(3.51%) 1(1.82%) 1.00
30-day mortality, n 0 0
Data are mean ± SD when appropriate. RVOT, right ventricle outflow tract; MAP, mean arterial pressure; CVP, central venous pressure; CPB, cardiopulmonary bypass; TACC
time, Total aortic cross-clamp time; ICU, intensive care unit; RPP, rate pressure product; IScore, Inotropic score; ALT, Alanine aminotransferase; ARF, acute renal failure;
LCOS, low cardiac output syndrome.
aThe temperature refer to minimum core body temperature.
*P< 0.05 vs. control group.
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stay, duration of hospital stay, mean arterial pressure, central venous
pressure (CVP), heart rate pressure product (RPP, the product of
heart rate and systolic blood pressure), and inotropic score were all
collected. Alanine aminotransferase and creatinine levels at 24 h after
the operation were used to assess postsurgical liver and kidney func-
tion, respectively. No significant differences were observed between
the two groups in terms of gender, body weight, age, cardiac colour
Doppler flow data or intra-operative monitoring parameters.
Patients in the control group needed longer ventilation time than the
RIPC group (35.02 ± 6.56 h vs. 31.96 ± 6.60 h, respectively, P= 0.016)
(Table 1 and Figure 2A). The length of stay in the ICU of the control
group was longer than that in the RIPC group (52.30 ± 13.43 h vs.
47.55 ± 10.34 h, P= 0.039) (Table 1 and Figure 2B). However, there
were no significant differences in the oxygenation index or duration
of hospital stay. The mean arterial pressures after operation did not
significantly differ between the two groups. However, patients in the
control group required moderately but significantly higher doses of
inotropes used to maintain haemodynamic stability immediately fol-
lowing surgery (14.17 ± 0.18 mcg/kg/min vs. 13.53 ± 0.19 mcg/kg/min,
P= 0.018) and at 6 h post-surgically (11.03 ± 0.18 mcg/kg/min vs.
10.51 ± 0.17 mcg/kg/min, P= 0.035) (Table 1). RPP, an indirect meas-
ure of myocardial oxygen consumption, was also significantly lower
in the RIPC group than in the control group at 12 h after the oper-
ation. Post-operative complications including hospital death (2 in the
control group vs. 1 in the RIPC group) did not significantly differ be-
tween the groups during the period of observation.
Systemic inflammatory response and
myocardial function and injury
As shown in Supplementary material online, Table S1, the levels of
plasma IL-10, IL-8, and TNF-a did not differ between the groups pre-
operatively (Preop). However, the secretion of IL-10 was significantly
increased post-operatively in both groups, but the values of post-
operative IL-10 in the RIPC group were significantly higher than those
in the control group at 12 h (P< 0.01). Significant elevations of IL-8
and TNF-a were observed in both groups post-operatively.
However, the levels of IL-8 (at 6 and 12 h) and TNF-a (at 6 and 12 h)
were significantly lower in the RIPC group than in the control group.
There were significant differences in terms of the time effects and
interactive effects between time and group for IL-10, IL-8, and TNF-
a. In addition, the secretion of IL-10, IL-8, and TNF-a were signifi-
cantly increased and reached maximal levels at 6 h after CPB
(PostCPB6h) and then gradually decreased but remained higher than
those at Preop group during the period of observation.
As shown in Table 2, the levels of post-operative TnT, CK-MB and
hFABP were significantly lower in the RIPC group than in the control
group at 6 h (hFABP), 12 h (TnT), 18 h (TnT), and 24 h (CK-MB),
post-operatively. There were significant differences in terms of the
time effects and interactive effects between time and group for TnT
and hFABP. Meanwhile, there was significant time effect but no signifi-
cant difference in terms of interaction between time and group for
CK-MB. In addition, the value of the area under the plasma concen-
tration time curve (AUC) for TnT in the RIPC group was significantly
lower than that in the control group (P< 0.05), while the values of
AUC for CK-MB and hFABP in the RIPC group were approximately
11.9%, 14.5% lower than those in the control group, but these differ-
ences did not reach statistical significance (P> 0.05, Table 2).
RVOT cardiac hif-1a and intracellular
pro-survival signalling protein expression
As shown in Figure 3A, cardiac Hif-1a expression was higher in the
RIPC group than that in the control group. Total protein amounts of
Akt, STAT3, STAT5, eNOS, and PTEN did not significantly differ be-
tween the groups (Figure 3B–F). However, the ratios of
Figure 2 Ventilation time curve (A) and ICU stay time curve (B). N= 57 in the control group and N= 55 in the RIPC group. *P< 0.05 vs. control
group.
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Figure 3 Protein expression of RVOT myocardium. (A): Hif-1a expression in the RIPC group is higher than that in the control group (P= 0.0008).
(B–E): RIPC group ratio of phosphorylated Akt (P= 0.0096), STAT3 (P= 0.0144), STAT5 (P= 0.0156), and eNOS (P= 0.0279) to total protein are
higher than that in the control group. (F): Phosphorylated PTEN shows no difference between the groups. n= 20 in the control and n= 19 in the
RIPC group. *P< 0.05 vs. control group.
................................................ .................................................. .....................................................
....................................................................................................................................................................................................................
Table 2 Myocardial injury factors
TnT (ng/mL) CK-MB (ng/mL) hFABP (ng/mL)
Control RIPC Control RIPC Control RIPC
Preop 0.12 ± 0.13 0.12 ± 0.10 0.15 ± 0.19 0.11 ± 0.10 3.82 ± 0.97 3.64 ± 1.13
PostCPB6h 3.93 ± 0.75# 3.42 ± 1.08# 0.87 ± 0.38# 0.74 ± 0.39# 183.2 ± 52.5# 143.7 ± 45.9*#
PostCPB12h 7.59 ± 1.42# 6.37 ± 1.93*# 2.17 ± 0.49# 1.85 ± 0.52# 52.2 ± 11.9# 45.6 ± 10.7#
PostCPB18h 6.44 ± 0.74# 4.21 ± 0.80*# 3.12 ± 0.66# 2.98 ± 0.44# 35.05 ± 6.54# 29.58 ± 6.69#
PostCPB24h 3.97 ± 0.85# 3.30 ± 1.07# 4.18 ± 0.86# 3.62 ± 0.87*# 28.7 ± 7.0# 30.3 ± 9.1#
PostCPB48h 1.92 ± 0.48# 1.71 ± 0.62# 0.69 ± 0.37# 0.52 ± 0.22# 14.7 ± 3.5# 15.4 ± 3.4#
AUC 22.9 ± 6.29 18.0 ± 7.90* 10.77 ± 4.05 9.49 ± 3.65 308.2 ± 173.2 263.6 ± 182.2
Values are mean ± SD. n= 20 in control and n= 19 in RIPC group. AUC, Area under curve; *P< 0.01 vs. corresponding control groups; #P< 0.01 vs. corresponding Preop
group. There were significant differences in terms of the time effects and interactive effects between time and group for TnT (Time: F = 312.28, P< 0.0001; Interaction:
F= 8.68, P< 0.0001) and hFABP (Time: F= 307.51, P< 0.0001; Interaction: F= 5.57, P< 0.001). Meanwhile, there was significant time effect but no significant difference in terms
of interaction between time and group for CK-MB (Time: F= 382.02, P < 0.0001; Interaction: F = 1.46, P = 0.2035).
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..phosphorylated to total (p:t) protein specifically probed for Akt,
STAT3, STAT5, and eNOS were greater in the RIPC group than
those in the control group (all P< 0.05). There were no significant dif-
ferences in either total PTEN or the ratio of phosphorylated PTEN
to total PTEN between the groups.
Mitochondrial ultrastructure of RVOT
myocardium
As shown in Figure 4 and see Supplementary material online, Table S2,
the mitochondrial ultrastructure was severely damaged in the control
group compared with the RIPC group as observed under transmis-
sion electron microscopy. Mitochondrial oedema was present in all
of the samples obtained from both groups, whereas the values of the
surface-to-volume ratios of mitochondria (Sv-ratioMi) and the cellular
oedema index (CEI) in the RIPC group were significantly lower than
those in the control group (all P< 0.05). However, 14 samples from
the control group were found to be extremely swollen with apparent
vacuolization compared to two samples from the RIPC group
(P< 0.001). No significant difference was observed in terms of bro-
ken mitochondria, abnormal contraction bands, myofibrillar fragmen-
tation, or myofibrillar lysis between the two groups.
Discussion
This study is the first to demonstrate the clinical effectiveness of
RIPC with a concomitant exploration of its mechanism in ToF chil-
dren undergoing open-heart surgery. RIPC attenuates myocardial IRI
and improves the short-term prognosis in those patients, and the
mechanism underlying likely involves the activation of Hif-1a, Akt,
STAT3, STAT5, and eNOS resulting in decreased mitochondrial
damage in children undergoing TOF repair surgery as summarized in
Figure 5.
Although experimental animal studies have demonstrated that
RIPC is beneficial, the cardioprotective effects of RIPC in patients
undergoing cardiac surgery have yielded contradictory results. The
first clinical application of RIPC in patients was reported in a random-
ized clinical trial (RCT) in children undergoing open-heart surgery
and it demonstrated that RIPC is cardioprotective with a decreased
inotrope requirement, decreased airway resistance and decreased
troponin levels.4 Subsequently, other RCTs have demonstrated myo-
cardial protection by RIPC against myocardial IRI in adult patients
undergoing coronary artery bypass graft surgery with CPB.5,6
However, other recent multicentre trials have failed to demonstrate
Figure 4 Ultrastructure of RVOT myocardium. (A): All the mitochondria exhibit swelling, with one also showing vacuolization; (B): Mitochondria
exhibit marked swelling; (C): A ruptured mitochondrion; (D): Distinct abnormal contraction of myofibrils; (E): Due to abnormal contraction, the myo-
fibrils snapped; (F): The structure of the myofibrils were disrupted, with lysis at the centre. The typical ultrastructural changes of the myocardium are
indicated by the arrow.
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..beneficial effects of RIPC for patients undergoing cardiac surgery.7,21–23
The two recent multicentre clinical trials reported negative effects of
RIPC.7,8 The most plausible explanation for the lack of cardioprotec-
tion of RIPC in these two trials was the concomitant use of propofol
anaesthesia24,25 in all patients in the study of Meybohm et al.8 and in ap-
proximately 90% of patients in the study of Hausenloy et al.,7 although
the inclusion of many patients who not only underwent CABG but
also more traumatic valve surgery that caused direct damage to the
hearts was another concern.25 The intravenous anaesthetic propofol
possesses antioxidant properties that could obscure the effects of
RIPC. Indeed, RIPC, when applied during isoflurane but not during pro-
pofol anaesthesia, reduced myocardial damage in patients undergoing
CABG surgery.26 RIPC conferred cardioprotection along with cardiac
STAT5 activation under isoflurane anaesthesia, but neither RIPC cardi-
oprotection nor STAT5 activation were observed under propofol an-
aesthesia.10 In clinical trials reporting protective effects of RIPC, the
RIPC procedure was either completed without anaesthetic interven-
tion during the transportation of patients to the hospital (which would
allow more time for RIPC to take effect while avoiding the anaesthetic
interaction27), or completed during anaesthesia induction with inhala-
tional anaesthetics other than propofol.6 Given that adult patients
receiving cardiac surgeries generally present with comorbidities such
as diabetes and hypertension that may influence the RIPC-induced car-
dioprotective effects,28 the contradictory effects of RIPC in clinical set-
tings suggest that the cardioprotective effects of RIPC may also be
specific to the patient or disease. Meanwhile, cardioprotective man-
oeuvres such as ischaemic pre- and postconditioning lose their effect-
iveness with ageing.29 Ageing affects cardiomyocytes at several
subcellular and molecular levels, including alterations at the DNA level,
increased oxidative stress [reactive oxygen species (ROS) formation],
and age-related damage of mitochondrial function.29 Thus, children
may be more sensitive to protection by RIPC than adults. In several
clinical trials that showed no beneficial effects of RIPC in children
undergoing open-heart surgery, the sample sizes were either too small
to detect between-group differences as summarized in a meta-analysis
article,22 or RIPC was conducted in the presence of propofol anaesthe-
sia,30 or the RIPC stimulus was inflation of the blood pressure cuff
to 15 mm Hg above systolic pressure31 rather than 30 mm Hg
above systolic pressure, as used in our current study and in other
studies.
In our study, we utilized a uniform patient cohort to evaluate the
cardiac protective effects of RIPC. The need for longer ventilation
times is usually a consequence of cardiopulmonary dysfunction or
slower recovery after cardiac surgery, while the need for higher
doses of inotropes to maintain haemodynamic stability reflects
poorer cardiac function. In addition, both the duration of intubation
and the inotrope requirement can be considered as independent pre-
dictors of a prolonged ICU stay.12 Reduction in ventilation time and
inotropes requirement suggested that RIPC improved the cardiac
function and improved the short-term prognosis. We found that the
Figure 5 Schematic of proposed signalling involved in remote ischaemic preconditioning cardioprotection (RIPC) in ToF children undergoing
elective radical ToF repair surgery. RIPC reduces the postoperative cardiac ischaemic injury through activating the PI3K/Akt and JAK/STAT3/5 signal-
ling pathways, which is associated with nuclear accumulation of Hif-1a and STAT3/5 and subsequent induction of myocardial eNOS activation and
mitochondrial protection.
8 Q. Wu et al.
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concentrations of TnT, CK-MB, and hFABP, indicators of myocardial
damage, were significantly lower in the RIPC group than those in the
control group. These results suggested that RIPC attenuated myocar-
dial IRI and improved the short-term prognosis and also potentially
long-term prognosis as well in ToF children undergoing open-heart
surgery, although the underlying mechanism remains unclear.
Endothelial dysfunction and impairment of the mechanical proper-
ties of the lungs following CPB have been proposed as the mechan-
isms for RIPC-mediated shortening of postoperative ventilation
duration.32,33 RIPC has been shown to confer cardioprotection by
reducing neutrophil activation and endothelial dysfunction in patients
with valve replacement surgery.34 In our current study, IL-10 levels
were increased with a reduction in IL-8 and TNF-a in the RIPC group
when compared with the control group. Studies have shown that
RIPC induces late protection against myocardial IRI by increasing the
expression of IL-10 in the remote muscle, followed by the release of
IL-10 into the circulation, and activation of protective signalling path-
ways in the heart.35 Excessive TNF-a expression induces contractile
dysfunction and cell death, while a lower TNF-a concentration is
protective.36,37 Furthermore, in vivo dog experiments have demon-
strated time-dependent myocardial dysfunction following intraven-
ous infusion of TNF-a.38,39 Importantly, the overall response is
modulated by the anti-inflammatory cytokine IL-10 and pro-
inflammatory cytokine IL-840 through the inhibition of the expression
of TNF-a. The current data are consistent with an acute modification
of inflammatory pathways in RIPC.
The transcription factor hypoxia-inducible factor (Hif)-1 has
emerged as a central oxygen-sensitive transcription factor involved in
the protective response to hypoxia.41,42 Hif-1 is composed of Hif-1a
and Hif-1b subunits. Whereas Hif-1b is constitutively expressed, Hif-
1a is up-regulated in response to hypoxia. Under normoxic condi-
tions, Hif-1a stability and transcriptional activity are inhibited.43,44 In
our study, there was no difference in the aortic overriding ratio,
RVOT width, or SpO2 before surgery between the RIPC group and
the control group. However, the RVOT myocardial Hif-1a protein
expression in the RIPC group was higher than that in the control
group. This result was consistent with a previous study showing that
RIPC increased Hif-1a levels in the right atrial tissue of patients
undergoing heart surgery.45 However, whether or not RIPC-induced
cardioprotection requires the up-regulation of Hif-1a remains un-
known and merits further study.
Although the mechanistic pathways underlying RIPC cardioprotec-
tion remain unclear, studies suggest a neuro-hormonal pathway that
may link the RIPC stimulus to the heart. The reperfusion injury signal-
ling kinase pathway including the PI3K/Akt signalling cascade and the
protective survivor activating factor enhancement pathway including
the JAK2/STAT3 signalling cascade are the most important path-
ways involved in eNOS activation and ischaemia myocardial protec-
tion.46–48 A previous study has shown that STAT5, but not STAT3, is
activated by RIPC and becomes the unique signalling signature of
RIPC in humans.49 Our study demonstrated that RIPC could enhance
the phosphorylated Akt, STAT3, STAT5, and eNOS expression lev-
els in the RVOT myocardium of patients. These findings suggest that
RIPC reduces the postoperative cardiac ischaemic injury through
activating the prosurvival signalling pathway. However, Pepe et al.
performed RIPC in ToF children as young as 1 month who under-
went elective open heart surgery, and it was found that there were
no differences in phosphorylated Akt or STAT3 between the control
and RIPC-treated groups.50 The reasons for this discrepancy may be
due to the increased age of the ToF children in this study (the average
age was approximately 10 or 11 months in our study vs. an average
of approximately 7 months in the study of Pepe et al.). Additionally,
the timing of the RVOT tissue sampling may affect the detection of
changes in signalling proteins after the preconditioning stimuli, with
an elevation of pro-survival proteins at a relatively earlier phase of
reperfusion.50 As such, the timing of RVOT tissue sample collection
was set at a relatively early stage of CPB in the current study, while
the exact timing of RVOT tissue sample collection was not clear in
the study of Pepe et al. Therefore, the patterns of changes in the pro-
survival signalling proteins as well as how the pro-survival signalling
pathway mediated RIPC cardioprotection in ToF children merits fur-
ther study. Our finding that RIPC can also activate cardiac STAT3 in
humans is in line with a recent study that showed that long-term,
regular RIPC increased STAT3 activation in human arterial specimens
(presumably coronary artery fragments) discarded during CABG sur-
gery and improved endothelial function.51
The major determinant of cardiomyocyte death following an epi-
sode of IRI is mitochondrial dysfunction arising from the formation of
the mPTP,52–54 while inhibition of the mPTP is the hallmark of cardi-
oprotection.55 The opening of the mPTP results in mitochondrial de-
polarization, swelling, and ultimately apoptotic cell death with the
release of mitochondrial cytochrome C. In our study, we found all
the RVOT myocardial samples presented mitochondrial swelling,
however, more extreme swelling and even vacuolization of the mito-
chondria was observed in the control group, which suggested that
RIPC attenuated the mitochondrial injury and cellular death induced
by myocardial IRI in the clinical setting of children undergoing elective
radical ToF repair surgery.
Conclusions
Our randomized clinical trial of RIPC in ToF children undergoing
elective radical ToF repair surgery has demonstrated that RIPC can
reduce ventilation time, the duration of ICU stay, and improve heart
function after surgery. The increased cardiac Hif-1a expression and
enhanced phosphorylation of Akt, STAT3, STAT5 and eNOS expres-
sion, which can consequently improve mitochondrial function, may
be the major mechanisms whereby RIPC confers the cardioprotec-
tive effect in ToF children undergoing elective radical ToF repair
surgery.
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